Multivariate analysis of prognostic factors for progression-free and overall survival at the time of starting treatment with tafasitamab / lenalidomide in the efficacy cohort
| Multivariate analysis (ITT cohort) . | PFS . | OS . | ||
|---|---|---|---|---|
| HR (95%CI) . | P . | HR (95%CI) . | P . | |
| ECOG PS 2-4 | 2.1 (1.3-3.6) | 0.003 | — | — |
| Previous line Refractory/progressing | 2.1 (1.2-3.6) | 0.006 | 3.7 (1.9-7.1) | <0.001 |
| Double-hit HGL | 2.5 (1-5.9) | 0.039 | 3.7 (1.4-9.8) | 0.007 |
| R-IPI 3-5 at T/L | — | — | 3.2 (1.7-5.9) | <0.001 |
| Multivariate analysis (ITT cohort) . | PFS . | OS . | ||
|---|---|---|---|---|
| HR (95%CI) . | P . | HR (95%CI) . | P . | |
| ECOG PS 2-4 | 2.1 (1.3-3.6) | 0.003 | — | — |
| Previous line Refractory/progressing | 2.1 (1.2-3.6) | 0.006 | 3.7 (1.9-7.1) | <0.001 |
| Double-hit HGL | 2.5 (1-5.9) | 0.039 | 3.7 (1.4-9.8) | 0.007 |
| R-IPI 3-5 at T/L | — | — | 3.2 (1.7-5.9) | <0.001 |
Abbreviations: PFS: progression-free survival; OS: overall survival; HR: hazard ratio; 95%CI: 95% confidence interval; HGL: high-grade lymphoma; ECOG: Eastern cooperative oncology group; PS: performance status; R-IPI: revised International Prognostic Index; T/L: tafasitamab lenalidomide.